FDA clears AIE's image enhancement technology

AIE Press Release
Cutler and Company (Andy Cutler)

September 6, 2006

AIE today announced the Food and Drug Administration (FDA) has cleared the Company's premarket notification (510k) for its image enhancement software. Breast cancer is the most common cancer diagnosed in women, besides skin cancer. Mammography is the best available method for early detection, although abnormalities can still be hard to detect in dense breasts. AIE CEO Michael Duarte stated "Our software enhances digital mammography images, making abnormalities easier to locate, even in dense breasts."

Researchers from Newton-Wellesley Hospital, Brigham and Woman’s Hospital, Massachusetts General Hospital and Faulkner Hospital, in late 2005 evaluated the use of AIE's software program with digital mammography to see if detection could be improved. The radiologists rated AIE's software superior (to without) in 88 percent of the cases for improving the conspicuity and detail of calcifications. The researchers believe the results indicate the software may be valuable in helping physicians detect breast cancer more accurately.